Personal paper. New drug treatment for Alzheimer's disease: Lessons for healthcare policy

British Medical Journal

Volumn 316, Issue 7133, 1998, Pages 762-764

  Melzer, David ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COST OF ILLNESS; DRUG COST; DRUG MARKETING; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; SHORT SURVEY; ADVERTIZING; AGED; BIOMEDICAL AND BEHAVIORAL RESEARCH; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HUMAN EXPERIMENT; INFORMATION DISSEMINATION; MENTAL HEALTH THERAPIES; NATIONAL HEALTH SERVICE; PROFESSIONAL PATIENT RELATIONSHIP; PUBLISHING; REVIEW; RISK ASSESSMENT; UNITED KINGDOM; UNITED STATES;

ARICEPT; BIOMEDICAL AND BEHAVIORAL RESEARCH; MENTAL HEALTH THERAPIES; NATIONAL HEALTH SERVICE; PROFESSIONAL PATIENT RELATIONSHIP;

ADVERTISING; AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; EDITORIAL POLICIES; EVIDENCE-BASED MEDICINE; GOVERNMENT REGULATION; GREAT BRITAIN; HEALTH POLICY; HUMANS; INDANS; INFORMATION DISSEMINATION; PIPERIDINES; RISK ASSESSMENT; THERAPEUTIC HUMAN EXPERIMENTATION; UNITED STATES;

EID: 0032492253     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.316.7133.762     Document Type: Short Survey

References (20)

1. Rogers SL, Doody R, Mohs R, Friedhoff L. E2020 produces both clinical global and cognitive test improvements in patients with mild to moderate Alzheimer's disease. Neurology 1996;46(suppl):A217.
2. Fletcher D, Irwin A. Alzheimer's drug too dear for NHS. Daily Telegraph 1997 April 5:9.
3. Ferriman A. Alzheimer's drug a success, but at what price? Independent 1997 March 28:13.
4. Toynbee P. Life or death? We must all decide. Independent 1997 February 12:13.
5. Eaton L. HAs call extra finding to meet £200m cost of Alzheimer's drug. Health Serv J 1997;107:6.
6. Laurance J. First Alzheimer's drug could cost £1.200 per year. Times 1997 March 28:6.
7. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs. 1st draft. Rockville, MD: US Drug and Food Administration, 1990.
8. Schneider LS. An overview of the rating scales used in dementia research. Alzheimer Insights 1996;2:17.
9. Kelly CA, Harvey RJ, Cayto H. Drug treatments for Alzheimer's disease. BMJ 1997;314:693-4.
10. Eisai Corporation. Aricept (donepezil hydrochloride tablets). Full prescribing information leaflet - USA. Teaneck, NJ: Eisai Corporation, 1996.
11. Gray S. Advertisement for donepezil (Aricept) in the BMJ. BMJ 1997;314:1555.
12. Wagner N. Advertisement for donepezil (Aricept) in the BMJ. BMJ 1997;314:1555-6.
13. Rittenhouse B. Uses of models in economic evaluation of medicine and other health technologies. London: Office of Health Economics, 1996.
14. Tugwell P, Sitthi-Athorn C, O'Connor A, Hatcher-Roberts J, Bergevin Y, Wolfson M. Technology assessment: old, new and needs based. Int J Technol Assess 1995;11:650-62.
15. Rubenstein L, Nasr S. Health service use in physical illness. In: Ebrahim S, Kalache A, eds. Epidemiology in old age. London: BMJ Publishing Group, 1996;106-25.
16. Impallomini M, Starr J. The UK Community Care Act (1990) and the elderly. Lancet 1994;334:1230.
17. Bartlett H, Phillips D. Policy issues in the private health sector: examples from long term care in the UK. Soc Sci Med 1996;13:731-7.
18. Murphy E. A more ambitious vision for residential long-term care. Int J Geriatric Psychiatry 1992;7:851-2.
19. Abel-Smith B. The escalation of health care costs: how did we get here? In: Health care reform. The will to change. Paris: Organisation for Economic Cooperation and Deveploment, 1996:17-30.
20. Wise J. Research suppressed for seven years by drug company. BMJ 1997;314:1145.